Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Williams developed SNT to address the lack of rapid treatments for acute psychiatric emergencies. Traditional TMS is given once daily for 6 weeks, which he argues is like studying a little bit each day for months—less effective than cramming. By applying spaced learning theory (reviewing material every hour), they compressed the entire course into 5 days, giving 5 times the normal dose. The protocol involves 10 stimulation sessions per day, each lasting about 9 minutes, spaced an hour apart. In open-label and controlled trials, 60–90% of patients achieved full remission (normal mood) within 1–5 days. Some patients have remained in remission for up to 4 years. The treatment is well-tolerated with no cognitive side effects; patients report feeling 'back to normal.' Williams emphasizes that the device is just a conduit; the therapeutic agent is the specific stimulation protocol in the correct brain region. This approach represents a shift from chronic management to an acute intervention that can break the depressive episode.

Williams discusses the evolution of psychedelic research, noting that early neuroimaging surprised researchers by showing decreased, not increased, brain activity. The key finding is the change in connectivity patterns. He compares psilocybin's effects to TMS, both converging on the same circuit. In open-label studies, 50–67% of patients improve; in blinded trials, about 33%. The effects can be long-lasting, unlike ketamine which typically lasts only 1.5 weeks per infusion. Williams sees psilocybin as part of 'psychiatry 3.0' because it directly targets brain circuits rather than correcting a chemical imbalance. The experience often involves spontaneous insights and a new perspective on old problems, which patients then integrate. He stresses that these substances must remain within strict medical supervision, as they are too powerful for recreational use.

Williams cites the MAPS trials showing that about two-thirds of participants had clinically significant improvement in PTSD, with effects lasting years for some. He contrasts this with ketamine, which only lasts about 1.5 weeks per infusion. MDMA's ability to produce lasting change after just a few sessions makes it particularly compelling. He notes that the therapeutic context is critical: the drug enables a state where patients can re-examine trauma with empathy and detachment, leading to spontaneous insights and emotional release. This aligns with the circuit model—by temporarily altering brain connectivity, MDMA allows the prefrontal cortex to properly process and integrate traumatic memories that were previously stuck in a hyper-reactive limbic loop. Williams emphasizes that these substances must be kept within strict medical boundaries, as they are not recreational and carry risks if misused.

Williams describes ibogaine as perhaps the most potent psychedelic, used traditionally in Gabon. It is not recreational; users undergo a grueling life review lasting up to 36 hours, often described as '10 years of psychotherapy in a night.' His team is conducting the first human neurobiological study in former Navy SEALs and Army Rangers, collecting clinical scales, neurocognitive tests, neuroimaging, and EEG. Preliminary anecdotes are dramatic: soldiers who accidentally caused civilian casualties report forgiving themselves for the first time. This addresses 'moral injury,' a unique aspect of combat trauma that standard PTSD treatments often miss. The cardiac risk has limited research, but Williams believes that with proper screening, the risk can be managed. He emphasizes that ibogaine must never be used recreationally and requires strict medical oversight. The study aims to quantify these effects and understand the brain mechanisms, potentially opening a new avenue for treating intractable guilt and trauma.

Williams explains the fascinating ethnobotanical discovery: two plants that individually are inactive combine to produce a powerful psychedelic. The MAOI component is reversible, which is crucial because irreversible MAOIs would cause serotonin syndrome if combined with DMT. Ayahuasca is used as a sacrament in syncretic religions in Brazil. A Brazilian study gave prisoners either ayahuasca or placebo and found significantly lower recidivism rates in the ayahuasca group, suggesting a lasting effect on criminal behavior. Williams is cautious, noting this is an 'edgy' study and not a recommendation for widespread use, but it raises questions about what drives behavioral change. He also mentions research showing no neurocognitive deficits in children exposed to low doses in tribal contexts, suggesting relative safety when used traditionally. The mechanism likely involves the same circuit-level changes seen with other psychedelics, but the specific cultural and ritual context may also play a role.

Williams argues that both TMS and psychedelics work by directly modulating brain circuits—specifically, restoring the prefrontal cortex's ability to govern deeper limbic regions like the anterior cingulate. In depression, the conflict-detection system (cingulate) overpowers the prefrontal 'governor', leading to spontaneous negative content. Effective treatments re-time the left dorsolateral prefrontal cortex over the cingulate, and the degree of this re-regulation correlates with antidepressant effect. This circuit-level view means the problem is not a missing chemical but a dysregulated network that can be recalibrated. Patients report feeling that they are not chronically broken, and that relapse is just a need for a 'tune-up' rather than a sign of permanent imbalance. The model also explains why psychotherapy works in milder cases—it endogenously strengthens prefrontal control—while TMS or psychedelics exogenously impose that control.

Williams describes that in his accelerated TMS protocol (Saint/SNT), some patients who remit early in the week—by Wednesday—report by Thursday or Friday that they spontaneously went to the beach and sat 'totally present in the present moment for an hour.' One patient explicitly said he had read about this in mindfulness books but never experienced it until that night. Williams has now seen this in five or six individuals over a couple of years. He does not have full scientific data on the phenomenon but finds it intriguing that pushing people past clinical wellness can yield this additional set of features. This anecdote aligns with the idea that the prefrontal cortex, when properly regulated, can naturally produce states of focused, non-judgmental awareness, potentially explaining why TMS and meditation might share overlapping mechanisms.

Williams explains that ibogaine, derived from the iboga tree root bark in Gabon, induces a 'life review' where individuals re-experience earlier life memories with detached empathy, seeing themselves almost as a third party. It is described as '10 years of psychotherapy in a night' and lasts 24–36 hours. It is not recreational; users find it hard work but relieving. His team has been evaluating former special operations personnel with full clinical scales, neurocognitive batteries, neuroimaging, and EEG before and after ibogaine. Although data analysis is incomplete, early anecdotes are dramatic: soldiers who accidentally caused civilian casualties report forgiving themselves for the first time. This suggests ibogaine may allow reprocessing of traumatic memories from a compassionate perspective, decoupling the intense guilt from the self-representation. The cardiac risk (QT prolongation) requires careful ECG screening, which is why it has been understudied.

Williams references work by David Nutt and Robin Carhart-Harris showing that psilocybin decreases brain activity but increases global connectivity. His own TMS research found that effective stimulation down-regulates the connectivity between the subgenual anterior cingulate (a region involved in negative mood) and the default mode network (involved in self-referential thought). In depression, these two systems become over-connected, making people feel stuck in negative self-representations. Post-psilocybin, the same connectivity change is observed. This suggests that both treatments 'unpair' the conflict/negative affect system from the sense of self, allowing more flexible thinking. The finding supports a circuit-based model where the specific target is this connection, and it explains why both TMS and psychedelics can produce rapid, sustained relief without ongoing drug administration.

Williams explains that his lab measures brain-heart connections using TMS. When they stimulate the dorsolateral prefrontal cortex, they can decelerate heart rate, demonstrating a direct neural pathway from the mood-regulatory region to the heart via the vagus nerve. This pathway goes from dorsolateral prefrontal cortex to anterior cingulate, insula, amygdala, nucleus tractus solitarius, and ultimately the vagus nerve. This connection is specific to that prefrontal region; stimulating visual or motor cortex does not produce the same effect. The finding has been replicated multiple times. This biological link may explain why depression worsens cardiovascular outcomes and why treating depression could improve heart health. It also underscores that the mind-heart connection is not 'woo' but a measurable, physical circuit.